USP5 negatively regulates the activation of NLRP3 inflammasomes and participates in the pathological and physiological processes of Sjogren's syndrome
- 20 May 2024
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 135, 112274
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- NLRP3: A promising therapeutic target for autoimmune diseasesAutoimmunity Reviews, 2018
- Hyperactivation of the NLRP3 Inflammasome in Myeloid Cells Leads to Severe Organ Damage in Experimental LupusThe Journal of Immunology, 2017
- Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritisArthritis Research & Therapy, 2015
- Anti-TNF Treatment Response in Rheumatoid Arthritis Patients Is Associated with Genetic Variation in the NLRP3-InflammasomePLOS ONE, 2014
- Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatmentAnnals of the Rheumatic Diseases, 2014
- Activation and regulation of the inflammasomesNature Reviews Immunology, 2013
- Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developmentsCurrent Opinion in Immunology, 2013
- The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosisArthritis & Rheumatism, 2011
- Inflammasomes and autoimmunityTrends in Molecular Medicine, 2011
- Horror Autoinflammaticus: The Molecular Pathophysiology of Autoinflammatory DiseaseAnnual Review of Immunology, 2009